Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
Lung Cancer. 2015 Jun;88(3):349-51. doi: 10.1016/j.lungcan.2015.03.012. Epub 2015 Mar 20.
Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.
克唑替尼是首个临床可用的间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂，而新一代的 ALK 抑制剂，如阿来替尼，目前正在研发中。虽然克唑替尼通常具有良好的耐受性，但已有报道称严重的食管损伤是克唑替尼治疗的罕见但严重的不良事件。我们现在描述了使用阿来替尼成功治疗一名发生克唑替尼诱导的食管溃疡的患者。
